Consistent with clinical observations, tacrolimus administration reliably induces diabetes in rodent models by disrupting key β-cell signaling pathways, including CaN/NFAT and PI3K/AKT/mTOR, which collectively impair β-cell function (51, –, 54). The gene discussed is AKT1; the disease is diabetes mellitus.